secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2024-12-09T23:59:59+00:00
Accession:  0001628280-24-050499
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves simplified dosing regimen for Cumberland's Acetadote IV NAC
------------------------------------------------------------------------

- FDA approved sNDA for Acetadote on Dec 9, 2024; new regimen combines first two bags into a single slower infusion.
- New dosing aims to reduce medication errors and non-allergic anaphylactoid reactions (NAARs) without compromising efficacy.
- Acetadote indicated to prevent/lessen liver injury after acetaminophen overdose, the leading cause of acute liver failure in the US.
- Cumberland Pharmaceuticals (CPIX) specialty pharma; CEO A.J. Kazimi highlighted commitment to improving patient care.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000162828024050499/0001628280-24-050499-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000162828024050499/cpix-20241209.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-050499

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer